PRT062607 (Hydrochloride)

PRT062607 (P505-15) Hydrochloride is an orally available Syk inhibitor (IC50: 1 nM) that inhibits inflammation and induction Apoptosis. PRT062607 Hydrochloride exerts potent antitumor activity in tumor xenograft mouse models[1][2].

Product Specifications

CAS Number

[1370261-97-4]

Product Name Alternative

P505-15 Hydrochloride

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; FAK; Mixed Lineage Kinase; PAK; Pyk2; Src; Syk

Type

Reference compound

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Cytoskeleton; MAPK/ERK Pathway; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/PRT062607-Hydrochloride.html

Purity

99.02

Solubility

10 mM in DMSO|DMSO : ≥ 33 mg/mL|H2O : ≥ 50 mg/mL

Smiles

NC(C1=CN=C(N[C@H]2[C@@H](N)CCCC2)N=C1NC3=CC=CC(N4N=CC=N4)=C3)=O.[H]Cl

Molecular Formula

C19H24ClN9O

Molecular Weight

429.91

Precautions

H302, H315, H319, H335

References & Citations

[1]Spurgeon SE, et al. The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia. J Pharmacol Exp Ther. 2013 Feb;344 (2) :378-87.|[2]Coffey G, et al. Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis. J Pharmacol Exp Ther. 2012 Feb;340 (2) :350-9.

Shipping Conditions

Room Temperature

Storage Conditions

4°C (Powder, sealed storage, away from moisture)

Scientific Category

Reference compound1

Clinical Information

Phase 2

Isoform

Lck; PAK5

Citation 01

Harvard Medical School LINCS LIBRARY|Int J Ophthalmol. 2022 Jul 18;15 (7) :1044-1052.|Cell Death Dis. 2025 Aug 7;16 (1) :595.|Proc Natl Acad Sci U S A. 2022 Oct 25;119 (43) :e2207280119.